<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093794</url>
  </required_header>
  <id_info>
    <org_study_id>0431A-122</org_study_id>
    <secondary_id>2010_518</secondary_id>
    <nct_id>NCT01093794</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)</brief_title>
  <official_title>A Bioequivalence Study With Two Tablet Strengths of the Final Market Image (FMI) Sitagliptin/Metformin Fixed Dose Combination (FDC) Tablet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that the Final Market Image (FMI) sitagliptin/metformin
      50 mg/500 mg and 50 mg/850 mg (Fixed Dose Combination) FDC tablet and co-administration of
      corresponding doses of sitagliptin and China-sourced metformin as individual tablets will be
      bioequivalent based on assessment of the AUC(0-t) and Cmax, for both sitagliptin and
      metformin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC(0-t)) for Sitagliptin</measure>
    <time_frame>baseline through 72 hours postdose</time_frame>
    <description>AUC (0-t) is the area under the curve for the plot showing plasma concentration against time from time zero to the time of the last quantifiable concentration for sitagliptin 50 mg, metformin 500 mg and metformin 850 mg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Sitagliptin and Metformin</measure>
    <time_frame>baseline through 72 hours postdose</time_frame>
    <description>Cmax is the peak serum concentration of a therapeutic drug after administration; and is used to determine the rate and extent of drug absorption. Cmax is reported for sitagliptin 50 mg, metformin 500 mg and metformin 850 mg.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:
Co-administration of 50 mg sitagliptin and 500 mg metformin
sitagliptin/metformin 50 mg/500 mg FDC tablet
sitagliptin/metformin 50 mg/850 mg FDC tablet
Co-administration of 50 mg sitagliptin and 850 mg metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:
sitagliptin/metformin 50 mg/500 mg FDC tablet
Co-administration of 50 mg sitagliptin and 850 mg metformin
Co-administration of 50 mg sitagliptin and 500mg metformin
sitagliptin/metformin 50 mg/850 mg FDC tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:
Co-administration of 50 mg sitagliptin and 850 mg metformin
sitagliptin/metformin 50 mg/850 mg FDC tablet
sitagliptin/metformin 50 mg/500 mg FDC tablet
Co-administration of 50 mg sitagliptin and 500mg metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:
sitagliptin/metformin 50 mg/850 mg FDC tablet
Co-administration of 50 mg sitagliptin and 500 mg metformin
Co-administration of 50 mg sitagliptin and 850 mg metformin
sitagliptin/metformin 50 mg/500 mg FDC tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Co-administration of 50 mg sitagliptin and 500 mg metformin</intervention_name>
    <description>Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.</description>
    <arm_group_label>1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850</arm_group_label>
    <arm_group_label>2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC</arm_group_label>
    <arm_group_label>3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500</arm_group_label>
    <arm_group_label>4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin/metformin 50 mg/500 mg tablet</intervention_name>
    <description>Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.</description>
    <arm_group_label>1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850</arm_group_label>
    <arm_group_label>2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC</arm_group_label>
    <arm_group_label>3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500</arm_group_label>
    <arm_group_label>4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Co-administration of 50 mg sitagliptin and 850 mg metformin</intervention_name>
    <description>Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.</description>
    <arm_group_label>1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850</arm_group_label>
    <arm_group_label>2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC</arm_group_label>
    <arm_group_label>3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500</arm_group_label>
    <arm_group_label>4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin/metformin 50 mg/850 mg tablet</intervention_name>
    <description>Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.</description>
    <arm_group_label>1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850</arm_group_label>
    <arm_group_label>2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC</arm_group_label>
    <arm_group_label>3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500</arm_group_label>
    <arm_group_label>4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is of Chinese descent

          -  Subject is in good health

          -  Subject is a non-smoker

        Exclusion Criteria:

          -  Subject has a history of stroke or chronic seizures

          -  Subject has a history of cancer

          -  Subject has had major surgery, donated blood or participated in another
             investigational study within the past 4 weeks
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2010</study_first_submitted>
  <study_first_submitted_qc>March 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2010</study_first_posted>
  <results_first_submitted>June 3, 2011</results_first_submitted>
  <results_first_submitted_qc>June 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2011</results_first_posted>
  <last_update_submitted>July 17, 2015</last_update_submitted>
  <last_update_submitted_qc>July 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>28 participants were randomized in four treatment sequences. Participants had a 7 day minimum washout period between treatments.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850</title>
          <description>Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:
Co-administration of 50 mg sitagliptin and 500 mg metformin
sitagliptin/metformin 50 mg/500 mg FDC tablet
sitagliptin/metformin 50 mg/850 mg FDC tablet
Co-administration of 50 mg sitagliptin and 850 mg metformin</description>
        </group>
        <group group_id="P2">
          <title>2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC</title>
          <description>Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:
sitagliptin/metformin 50 mg/500 mg FDC tablet
Co-administration of 50 mg sitagliptin and 850 mg metformin
Co-administration of 50 mg sitagliptin and 500mg metformin
sitagliptin/metformin 50 mg/850 mg FDC tablet</description>
        </group>
        <group group_id="P3">
          <title>3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500</title>
          <description>Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:
Co-administration of 50 mg sitagliptin and 850 mg metformin
sitagliptin/metformin 50 mg/850 mg FDC tablet
sitagliptin/metformin 50 mg/500 mg FDC tablet
Co-administration of 50 mg sitagliptin and 500mg metformin</description>
        </group>
        <group group_id="P4">
          <title>4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC</title>
          <description>Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:
sitagliptin/metformin 50 mg/850 mg FDC tablet
Co-administration of 50 mg sitagliptin and 500 mg metformin
Co-administration of 50 mg sitagliptin and 850 mg metformin
sitagliptin/metformin 50 mg/500 mg FDC tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6">After period 1, one participant was discontinued by the investigator due to a protocol deviation.</participants>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="5.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC(0-t)) for Sitagliptin</title>
        <description>AUC (0-t) is the area under the curve for the plot showing plasma concentration against time from time zero to the time of the last quantifiable concentration for sitagliptin 50 mg, metformin 500 mg and metformin 850 mg.</description>
        <time_frame>baseline through 72 hours postdose</time_frame>
        <population>Per-Protocol (PP) set: Participants who completed the study according to the protocol. One participant who discontinued after Treatment Period 1 was not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sit 50 mg + Met 500 mg</title>
            <description>Participants co-administered 50 mg sitagliptin and 500 mg metformin as individual tablets from all treatment sequences.</description>
          </group>
          <group group_id="O2">
            <title>SitMet 50mg/500mg FDC</title>
            <description>Participants administered the sitagliptin/metformin 50 mg/500 mg FDC tablet from all treatment sequences.</description>
          </group>
          <group group_id="O3">
            <title>Sit 50 mg + Met 850 mg</title>
            <description>Participants co-administered 50 mg sitagliptin and 850mg metformin as individual tablets from all treatment sequences.</description>
          </group>
          <group group_id="O4">
            <title>SitMet 50mg/850mg FDC</title>
            <description>Participants administered sitagliptin/metformin 50 mg/850 mg FDC tablet from all treatment sequences.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC(0-t)) for Sitagliptin</title>
          <description>AUC (0-t) is the area under the curve for the plot showing plasma concentration against time from time zero to the time of the last quantifiable concentration for sitagliptin 50 mg, metformin 500 mg and metformin 850 mg.</description>
          <population>Per-Protocol (PP) set: Participants who completed the study according to the protocol. One participant who discontinued after Treatment Period 1 was not included in the analysis.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sitagliptin 50 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1570" spread="217.40"/>
                    <measurement group_id="O2" value="1590" spread="186.58"/>
                    <measurement group_id="O3" value="1520" spread="228.83"/>
                    <measurement group_id="O4" value="1600" spread="195.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>metformin 500 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8350" spread="1881.70"/>
                    <measurement group_id="O2" value="8750" spread="1920.45"/>
                    <measurement group_id="O3" value="NA">Metformin 500 mg was not administered during this treatment.</measurement>
                    <measurement group_id="O4" value="NA">Metformin 500 mg was not administered during this treatment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>metformin 850 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Metformin 850 mg was not administered during this treatment.</measurement>
                    <measurement group_id="O2" value="NA">Metformin 850 mg was not administered during this treatment.</measurement>
                    <measurement group_id="O3" value="11800" spread="2849.36"/>
                    <measurement group_id="O4" value="13100" spread="2987.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Sitagliptin and Metformin</title>
        <description>Cmax is the peak serum concentration of a therapeutic drug after administration; and is used to determine the rate and extent of drug absorption. Cmax is reported for sitagliptin 50 mg, metformin 500 mg and metformin 850 mg.</description>
        <time_frame>baseline through 72 hours postdose</time_frame>
        <population>Per-Protocol (PP) set: Participants who completed the study according to the protocol. One participant who discontinued after Treatment Period 1 was not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sit 50 mg + Met 500 mg</title>
            <description>Participants co-administered 50 mg sitagliptin and 500 mg metformin as individual tablets from all treatment sequences.</description>
          </group>
          <group group_id="O2">
            <title>SitMet 50mg/500mg FDC</title>
            <description>Participants administered the sitagliptin/metformin 50 mg/500 mg FDC tablet from all treatment sequences.</description>
          </group>
          <group group_id="O3">
            <title>Sit 50 mg + Met 850 mg</title>
            <description>Participants co-administered 50 mg sitagliptin and 850mg metformin as individual tablets from all treatment sequences.</description>
          </group>
          <group group_id="O4">
            <title>SitMet 50mg/850mg FDC</title>
            <description>Participants administered sitagliptin/metformin 50 mg/850 mg FDC tablet from all treatment sequences.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Sitagliptin and Metformin</title>
          <description>Cmax is the peak serum concentration of a therapeutic drug after administration; and is used to determine the rate and extent of drug absorption. Cmax is reported for sitagliptin 50 mg, metformin 500 mg and metformin 850 mg.</description>
          <population>Per-Protocol (PP) set: Participants who completed the study according to the protocol. One participant who discontinued after Treatment Period 1 was not included in the analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sitagliptin 50 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189" spread="37.76"/>
                    <measurement group_id="O2" value="182" spread="38.71"/>
                    <measurement group_id="O3" value="187" spread="40.31"/>
                    <measurement group_id="O4" value="194" spread="32.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin 500 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1210" spread="323.83"/>
                    <measurement group_id="O2" value="1310" spread="383.57"/>
                    <measurement group_id="O3" value="NA">Metformin 500 mg was not administered during this treatment.</measurement>
                    <measurement group_id="O4" value="NA">Metformin 500 mg was not administered during this treatment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin 850 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Metformin 850 mg was not administered during this treatment.</measurement>
                    <measurement group_id="O2" value="NA">Metformin 850 mg was not administered during this treatment.</measurement>
                    <measurement group_id="O3" value="1790" spread="488.51"/>
                    <measurement group_id="O4" value="1970" spread="482.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sit 50 mg + Met 500 mg</title>
          <description>AEs reported in participants after co-administration of 50 mg sitagliptin and 500 mg metformin.</description>
        </group>
        <group group_id="E2">
          <title>Sit/Met 50 mg/500 mg FDC</title>
          <description>AEs reported in participants after administration of the sitagliptin/metformin 50 mg/500 mg fixed dose combination (FDC) tablet.</description>
        </group>
        <group group_id="E3">
          <title>Sit 50 mg + Met 850 mg</title>
          <description>AEs reported in participants after co-administration of 50 mg sitagliptin and 850 mg metformin.</description>
        </group>
        <group group_id="E4">
          <title>Sit/Met 50 mg/850 mg FDC</title>
          <description>AEs reported in participants after administration of sitagliptin 50 mg/metformin 850 mg FDC tablet.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leucocytosis</sub_title>
                <description>Laboratory finding</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. SPONSOR review can be expedited to meet publication guidelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

